Fig. 1From: Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension managementTime course of mean [20, 21] and median [17] heart rate changes from baseline, and mean [16, 20, 23] and median [17] blood pressure changes [17, 20, 23] from baseline in combretastatin A4-phosphate (CA4P) studies reporting such data. CA4P infusion occurred at time 0. Means of published data points are shown. Standard error of the mean is indicated with error barsBack to article page